~~<i id='851A4A9CA6'><strike id='851A4A9CA6'><tt id='851A4A9CA6'><pre id='851A4A9CA6'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：knowledge 2025-09-04 09:24:07 Page View：184

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What to know about the judge who will handle the Trump case
Next article： In age of alternative facts, a scholarly course on calling out crap

knowledge

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Illumina slashes 2023 revenue projections yet again

AdobeSANDIEGO—Afterstartingofftheyearwithlowerrevenueprojectionsthanmarketanalystshadhopedfor,SanDie

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

30 years of 'Listening to Prozac'

WhenProzacfirstenteredthepsychiatrysceneininthelate’80s,theprofessionwasstillFreud’sterritory.Manyco